Related references
Note: Only part of the references are listed.Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Giles W. Robinson et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.
Alexander E. Drilon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.
Cornelis Martinus van Tilburg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
Emiliano Cocco et al.
NATURE MEDICINE (2019)
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Theodore W. Laetsch et al.
LANCET ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Dazhi Liu et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma
David S. Ziegler et al.
BRITISH JOURNAL OF CANCER (2018)
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
Alexander Drilon et al.
CANCER DISCOVERY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
Miho J. Fuse et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
Alison M. Schram et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Implementing Genome-Driven Oncology
David M. Hyman et al.
CELL (2017)
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A. Drilon et al.
ANNALS OF ONCOLOGY (2016)
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
Maria Menichincheri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Elena Ardini et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis
Sadaf Ashraf et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
Amanda J. Redig et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Anna F. Farago et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Robert C. Doebele et al.
CANCER DISCOVERY (2015)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Aria Vaishnavi et al.
NATURE MEDICINE (2013)
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
Mark M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Phenotype of cerebellar glutamatergic neurons is altered in stargazer mutant mice lacking brain-derived neurotrophic factor mRNA expression
CA Richardson et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2005)
A de novo mutation affecting human TrkB associated with severe obesity and developmental delay
GSH Yeo et al.
NATURE NEUROSCIENCE (2004)
Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor
BJ Xu et al.
NATURE NEUROSCIENCE (2003)
Share Paper
